IP Library Granted Patent US 9,567,389
Granted Patent B2
US 9,567,389 · App. 13/781,917 · Granted Feb 14, 2017

Cell display of antibody libraries

Inventors: Changshou Gao (Gaithersburg, MD); Herren Wu (Gaithersburg, MD)
Assignee: MedImmune, LLC
C07K16/00C07K16/22C07K16/2842C07K16/2848C07K16/2866C07K16/005C07K2317/21C07K2317/622C07K2317/71C07K2317/732C07K2317/734C07K2319/03C07K2319/035C07K2319/30C12N15/1037
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,567,389
App. No.
13/781,917
Granted
Feb 14, 2017
Kind
B2
Abstract

The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.

Claims (20)

1. An isolated antibody comprising a human IgG1 Fc region having a reduced affinity for an effector molecule wherein said reduced affinity results from a one amino acid insertion in the Fc region wherein the amino acid insertion is between amino acid residues at positions selected from the group consisting of: (a) 230 and 231, (b) 238 and 239, (c) 239 and 240, and (d) 240 and 241, wherein the numbering is according to EU index as set forth in Kabat.

2. The antibody of claim 1 , wherein the effector molecule is selected from the group consisting of C1q, FcγRI, FcγRII and FcγRIIIA.

3. The antibody of claim 1 , wherein the antibody has reduced effector function.

4. The antibody of claim 3 , wherein the effector function is antibody-dependent cell-mediated cytotoxicity (ADCC).

5. The antibody of claim 1 , wherein the human IgG1 Fc region has a reduced affinity for C1q, FcγRI, FcγRII and FcγRIIIA.

6. The antibody of claim 5 , wherein the effector function is complement dependent cytotoxicity (CDC).

7. An Fc fusion protein comprising a human IgG1 Fc region having a reduced affinity for an effector molecule wherein said reduced affinity results from a one amino acid insertion in the Fc region wherein the amino acid insertion is between amino acid residues at positions selected from the group consisting of: (a) 230 and 231, (b) 238 and 239, (c) 239 and 240, and (d) 240 and 241, wherein the numbering is according to EU index as set forth in Kabat.

8. The Fc fusion protein of claim 7 , wherein the effector molecule is selected from the group consisting of C1q, FcγRI, FcγRII and FcγRIIIA.

9. The Fc fusion protein of claim 7 , wherein the human IgG1 Fc region has a reduced affinity for C1q, FcγRI, FcγRII and FcγRIIIA.

10. The Fc fusion protein of claim 7 , wherein the antibody has reduced effector function.

11. The Fc fusion protein of claim 10 , wherein the effector function is ADCC.

12. The Fc fusion protein of claim 10 , wherein the effector function is CDC.

13. The antibody of claim 1 , wherein the amino acid insertion is between 230 and 231.

14. The antibody of claim 1 , wherein the amino acid insertion is between 238 and 239.

15. The antibody of claim 1 , wherein the amino acid insertion is between 239 and 240.

16. The antibody of claim 1 , wherein the amino acid insertion is between 240 and 241.

17. The Fc fusion protein of claim 7 , wherein the amino acid insertion is between 230 and 231.

18. The Fc fusion protein of claim 7 , wherein the amino acid insertion is between 238 and 239.

19. The Fc fusion protein of claim 7 , wherein the amino acid insertion is between 239 and 240.

20. The Fc fusion protein of claim 7 , wherein the amino acid insertion is between 240 and 241.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2014
From: GAO, CHANGSHOU; WU, HERREN
To: MEDIMMUNE, INC.
Reel/Frame 034261/0030 →
CHANGE OF NAME Recorded Nov 25, 2014
From: MEDIMMUNE, INC.
To: MEDIMMUNE, LLC
Reel/Frame 034470/0659 →
Continuity (4)
Continuation 12837208 · Jul 15, 2010
Division 11580005 · Oct 13, 2006
Provisional Application 60726161 · Oct 14, 2005
Related Publication 20130231463A1 · Sep 5, 2013